Key terms

About EXEL

Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest EXEL news

Mar 21 6:20am ET Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), IDEAYA Biosciences (IDYA) and Vor Biopharma (VOR) Mar 11 11:13am ET Biotech Alert: Searches spiking for these stocks today Mar 04 12:20am ET 5 Best Biotech Stocks to Buy Now, According to Analysts – March 2024 Feb 27 7:01pm ET Exelixis exec Haley sells 47,020 common shares Feb 26 3:11pm ET Fly Insider: Exelixis, Akami among week’s notable insider trades Feb 26 3:11pm ET Fly Insider: Exelixis, Akami among week’s notable insider trades Feb 26 7:17am ET Truist Financial Keeps Their Buy Rating on Exelixis (EXEL) Feb 23 7:48am ET Maintaining Buy Rating on Exelixis Amid Patent Litigation and Strong Growth Prospects Feb 16 6:27am ET 5 Best Mid-Cap Stocks to Buy Now, According to Analysts – February 2024 Feb 12 8:20am ET Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), BeiGene (BGNE) and Catalent (CTLT) Feb 11 9:10pm ET Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL) and Envista Holdings (NVST) Feb 09 11:12am ET Biotech Alert: Searches spiking for these stocks today Feb 08 7:50am ET Analysts Offer Insights on Healthcare Companies: Idexx Laboratories (IDXX), Neurocrine (NBIX) and Exelixis (EXEL) Feb 08 1:02am ET A New Cause for Concern: Exelixis Adds a New Environmental / Social Risk Feb 08 12:30am ET Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), Enanta Pharmaceuticals (ENTA) and Steris (STE) Feb 07 9:25am ET Exelixis Earns Buy Rating on Strong Financials and Positive Outlook Feb 07 8:33am ET Exelixis: Hold Rating Amidst Pending Litigation and Pipeline Developments Feb 07 8:18am ET Piper Sandler Remains a Buy on Exelixis (EXEL) Feb 07 7:32am ET RBC Capital Sticks to Their Buy Rating for Exelixis (EXEL) Feb 07 7:21am ET Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Exelixis (EXEL) Feb 07 6:55am ET Exelixis Receives Buy Rating from David Lebovitz on Strong Financials and Growth Prospects Feb 07 5:31am ET Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), GE Healthcare Technologies Inc (GEHC) and Inspire Medical Systems (INSP) Feb 07 5:31am ET Buy Rating on Exelixis: Growth Prospects Amid Patent Rulings and Pipeline Developments Feb 07 5:21am ET Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Impedimed Limited (OtherIPDQF) Feb 07 2:45am ET Sell Rating on Exelixis Inc.: Caution Amid Lackluster Growth and Uncertain Product Efficacy Feb 06 4:18pm ET Exelixis backs FY24 revenue view $1.825B-$1.925B, consensus $1.91B Feb 06 4:17pm ET Exelixis reports Q4 adjusted EPS 33c, consensus 21c Feb 06 8:12am ET Cybrexa regains rights to CBX-12 Feb 02 8:10am ET Analysts Conflicted on These Healthcare Names: Exelixis (EXEL), Revvity (RVTY) and Becton Dickinson (BDX) Jan 30 5:26am ET Exelixis price target raised to $25 from $24 at Barclays Jan 29 11:10pm ET Analysts’ Opinions Are Mixed on These Healthcare Stocks: Crinetics Pharmaceuticals (CRNX), Exelixis (EXEL) and Fusion Pharmaceuticals (FUSN)

No recent press releases are available for EXEL

EXEL Financials

1-year income & revenue

Key terms

EXEL Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

EXEL Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms